Inflammatory bowel disease: an overview of immune mechanisms and biological treatments
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1155/2015/493012 http://hdl.handle.net/11449/131260 |
Resumo: | Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn's disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due to their increasing incidence. Recent studies have pointed out genes associated with IBD susceptibility that, together with environment factors, may contribute to the outcome of the disease. In ulcerative colitis, there are several therapies available, depending on the stage of the disease. Aminosalicylates, corticosteroids, and cyclosporine are used to treat mild, moderate, and severe disease, respectively. In Crohn's disease, drug choices are dependent on both location and behavior of the disease. Nowadays, advances in treatments for IBD have included biological therapies, based mainly on monoclonal antibodies or fusion proteins, such as anti-TNF drugs. Notwithstanding the high cost involved, these biological therapies show a high index of remission, enabling a significant reduction in cases of surgery and hospitalization. Furthermore, migration inhibitors and new cytokine blockers are also a promising alternative for treating patients with IBD. In this review, an analysis of literature data on biological treatments for IBD is approached, with the main focus on therapies based on emerging recombinant biomolecules. |
id |
UNSP_f90fc8d54837f81b52a360e5a7c451e2 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/131260 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatmentsInflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn's disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due to their increasing incidence. Recent studies have pointed out genes associated with IBD susceptibility that, together with environment factors, may contribute to the outcome of the disease. In ulcerative colitis, there are several therapies available, depending on the stage of the disease. Aminosalicylates, corticosteroids, and cyclosporine are used to treat mild, moderate, and severe disease, respectively. In Crohn's disease, drug choices are dependent on both location and behavior of the disease. Nowadays, advances in treatments for IBD have included biological therapies, based mainly on monoclonal antibodies or fusion proteins, such as anti-TNF drugs. Notwithstanding the high cost involved, these biological therapies show a high index of remission, enabling a significant reduction in cases of surgery and hospitalization. Furthermore, migration inhibitors and new cytokine blockers are also a promising alternative for treating patients with IBD. In this review, an analysis of literature data on biological treatments for IBD is approached, with the main focus on therapies based on emerging recombinant biomolecules.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Department of Genetics, Evolution and Bioagents, Institute of Biology, University of Campinas (UNICAMP), 13083-970 Campinas, SP, BrazilDepartment of Biomedical Science, Faculdade de Americana, Avenida Joaquim Boer 733, 13477-360 Americana, SP, BrazilMedical School, UNICAMP, 13083-887 Campinas, SP, BrazilDepartment of Biochemistry and Microbiology, Institute of Biosciences, Universidade Estadual Paulista (UNESP), Avenida 24 A 1515, 13506-900 Rio Claro, SP, Brazil.Department of Biochemistry and Microbiology, Institute of Biosciences, Universidade Estadual Paulista (UNESP), Avenida 24 A 1515, 13506-900 Rio Claro, SP, BrazilFAPESP: 2013/20258-2FAPESP: 2014/08591-0FAPESP: 2014/08619-2FAPESP: 2014/16701-0Hindawi Publishing CorporationUniversidade Estadual de Campinas (UNICAMP)Universidade Estadual Paulista (Unesp)Faculdade de Americana (FAM)Mattos, Bruno Rafael Ramos deGarcia, Maellin Pereira GracindoNogueira, Julia BierPaiatto, Lisiery NegriniAlbuquerque, Cassia GaldinoSouza, Caique LopesFernandes, Luís Gustavo RomaniTamashiro, Wirla Maria da Silva CunhaSimioni, Patricia Ucelli [UNESP]2015-12-07T15:33:09Z2015-12-07T15:33:09Z2015info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1-11application/pdfhttp://dx.doi.org/10.1155/2015/493012Mediators Of Inflammation, v. 2015, p. 1-11, 2015.1466-1861http://hdl.handle.net/11449/13126010.1155/2015/493012PMC4539174.pdf26339135PMC4539174PubMedreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengMediators Of Inflammation1,370info:eu-repo/semantics/openAccess2024-01-12T06:23:32Zoai:repositorio.unesp.br:11449/131260Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T22:44:50.432290Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatments |
title |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatments |
spellingShingle |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatments Mattos, Bruno Rafael Ramos de |
title_short |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatments |
title_full |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatments |
title_fullStr |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatments |
title_full_unstemmed |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatments |
title_sort |
Inflammatory bowel disease: an overview of immune mechanisms and biological treatments |
author |
Mattos, Bruno Rafael Ramos de |
author_facet |
Mattos, Bruno Rafael Ramos de Garcia, Maellin Pereira Gracindo Nogueira, Julia Bier Paiatto, Lisiery Negrini Albuquerque, Cassia Galdino Souza, Caique Lopes Fernandes, Luís Gustavo Romani Tamashiro, Wirla Maria da Silva Cunha Simioni, Patricia Ucelli [UNESP] |
author_role |
author |
author2 |
Garcia, Maellin Pereira Gracindo Nogueira, Julia Bier Paiatto, Lisiery Negrini Albuquerque, Cassia Galdino Souza, Caique Lopes Fernandes, Luís Gustavo Romani Tamashiro, Wirla Maria da Silva Cunha Simioni, Patricia Ucelli [UNESP] |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual de Campinas (UNICAMP) Universidade Estadual Paulista (Unesp) Faculdade de Americana (FAM) |
dc.contributor.author.fl_str_mv |
Mattos, Bruno Rafael Ramos de Garcia, Maellin Pereira Gracindo Nogueira, Julia Bier Paiatto, Lisiery Negrini Albuquerque, Cassia Galdino Souza, Caique Lopes Fernandes, Luís Gustavo Romani Tamashiro, Wirla Maria da Silva Cunha Simioni, Patricia Ucelli [UNESP] |
description |
Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn's disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due to their increasing incidence. Recent studies have pointed out genes associated with IBD susceptibility that, together with environment factors, may contribute to the outcome of the disease. In ulcerative colitis, there are several therapies available, depending on the stage of the disease. Aminosalicylates, corticosteroids, and cyclosporine are used to treat mild, moderate, and severe disease, respectively. In Crohn's disease, drug choices are dependent on both location and behavior of the disease. Nowadays, advances in treatments for IBD have included biological therapies, based mainly on monoclonal antibodies or fusion proteins, such as anti-TNF drugs. Notwithstanding the high cost involved, these biological therapies show a high index of remission, enabling a significant reduction in cases of surgery and hospitalization. Furthermore, migration inhibitors and new cytokine blockers are also a promising alternative for treating patients with IBD. In this review, an analysis of literature data on biological treatments for IBD is approached, with the main focus on therapies based on emerging recombinant biomolecules. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-12-07T15:33:09Z 2015-12-07T15:33:09Z 2015 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1155/2015/493012 Mediators Of Inflammation, v. 2015, p. 1-11, 2015. 1466-1861 http://hdl.handle.net/11449/131260 10.1155/2015/493012 PMC4539174.pdf 26339135 PMC4539174 |
url |
http://dx.doi.org/10.1155/2015/493012 http://hdl.handle.net/11449/131260 |
identifier_str_mv |
Mediators Of Inflammation, v. 2015, p. 1-11, 2015. 1466-1861 10.1155/2015/493012 PMC4539174.pdf 26339135 PMC4539174 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Mediators Of Inflammation 1,370 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
1-11 application/pdf |
dc.publisher.none.fl_str_mv |
Hindawi Publishing Corporation |
publisher.none.fl_str_mv |
Hindawi Publishing Corporation |
dc.source.none.fl_str_mv |
PubMed reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808129457599283200 |